SCHEMBL3003569

SCHEMBL3003569

O=S(=O)(c1cccc(Br)c1)C1CCN(c2nc(Cc3ccc(F)c(Cl)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 2/20 0.35
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TRPV1 Q8NER1 1/20 0.33
NPC1 O15118 2/20 0.33
CTSS P25774 1/20 0.33
HTR2A P28223 3/20 0.32
HTR2C P28335 2/20 0.32
KCNH2 Q12809 2/20 0.32
DRD2 P14416 1/20 0.32
MAPT P10636 1/20 0.32
MBTD1 Q05BQ5 1/20 0.32
L3MBTL3 Q96JM7 1/20 0.32
GPR6 P46095 1/20 0.32
AR P10275 1/20 0.32
CLPP Q16740 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001961 0.94 HTR2A (0.34) SOS1PKMPKLRRAB9ASMN1; SMN2
SCHEMBL3014287 0.93 RAB9A (0.33) PKMPKLRRAB9ASMN1; SMN2NPC1
SCHEMBL3021350 0.92 RAB9A (0.34) PKMPKLRRAB9ASMN1; SMN2NPC1
SCHEMBL3016075 0.92 L3MBTL1 (0.35) RAB9ASMN1; SMN2NPC1HTR2AMAPT
SCHEMBL3017451 0.92 RAB9A (0.38) SOS1PKMPKLRRAB9ASMN1; SMN2
SCHEMBL3004452 0.91 GPR6 (0.39) SOS1PKMPKLRRAB9ASMN1; SMN2
SCHEMBL3022500 0.91 HTR2A (0.37) SOS1RAB9ASMN1; SMN2TRPV1NPC1
SCHEMBL3008542 0.90 MAPT (0.36) RAB9ASMN1; SMN2NPC1HTR2AHTR2C
SCHEMBL3009255 0.90 HTR2A (0.37) SOS1PKMPKLRRAB9ASMN1; SMN2
SCHEMBL3004812 0.89 RAB9A (0.36) RAB9ASMN1; SMN2NPC1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SOS1 715/4885PKM 1047/4885PKLR 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.